Novo Nordisk, Eli Lilly Report GLP-1 Signals of Slowed Biological Aging at ARDD

Two major pharmaceutical companies presented early clinical molecular data at the Aging Research & Drug Discovery meeting indicating their GLP-1-based weight-loss drugs are associated with slower biological aging on multiple clock measures. Novo Nordisk reported proteomic-clock analyses from 10,052 participants (drug vs placebo) showing overall biological-age reductions of roughly two to three years and up to four years on a heart-specific protein clock, with effects emerging within 13-20 weeks and persisting or growing through 150 weeks; modeled from SELECT and a UK cohort of 19,117, remaining life-year gains averaged about 1.9 years. Eli Lilly’s epigenetic sub-study inside SURMOUNT-5 used paired whole-blood methylation at baseline and week 72 (≈1.38 years), analyzing 82 subjects (71 with paired samples), and found all 15 clocks trended toward less aging than elapsed time, with two clocks reaching statistical significance (median gains ~1.1 and 0.7 years), DunedinPACE declining, organ-specific clocks favoring immune, kidney, liver and cardiovascular age, and 21 EpiScore proteins shifting toward reduced innate inflammation.

Both datasets are explicitly preliminary and limited: Lilly’s arm was small, single‑arm and uncontrolled, follow-up is short relative to some clock measurement error, some predicted protein changes did not match measured levels, and clocks weren’t trained on randomized longitudinal trial data. Leading clock researchers called the magnitude notable but urged caution about generalizing to healthy or non-obese populations; larger, randomized and longer studies are planned or funded (including a $38M ARPA‑H effort) to test whether GLP-1 agents could serve as true geroprotectors and to clarify safety and regulatory pathways.